Latest
issue
GET ATTRACTIONS MANAGEMENT
magazine
Yes! Send me the FREE digital edition of Attractions Management and the FREE weekly Attractions Management ezines and breaking news alerts!
Not right now, thanksclose this window I've already subscribed. I've already subscribed.
Get Attractions Management digital magazine FREE
Sign up here ▸
Jobs   News   Features   Products   Company profilesProfiles   Magazine   Handbook   Advertise    Subscribe  
NEWS
Experimental drug increases metabolic rate: study
POSTED 09 Mar 2015 . BY Helen Andrews
While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome Credit: Shutterstock / Andresr
An experimental drug has been found to speed up metabolism and burn off fat cells, according to a study conducted on hundreds of mice by the Houston Methodist Research Institute, US.

Dubbed ‘GC-1’, the drug works by activating the receptors for thyroid hormone, which play a role in regulating the metabolism – the body’s conversion of food into energy.

“CG-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat,” said the study’s author Kevin Phillips PhD.

Until several years ago, scientists thought that only animals and human infants had energy-burning “good” brown fat.

“It is now clear,” said Phillips, “that human adults do have brown fat, but it appears to lose its calorie-burning capacity over time.”

White adipose tissue, or fat, becomes a “metabolic villain” when the body has too much of it, according to Phillips. People with more brown fat have a reduced risk of obesity and diabetes, thus researchers are now working on ways to convert white fat into brown fat.

Phillips and other researchers tested the drug on hundreds of mice, with partial funding from the National Institutes of Health, according to ScienceDaily. Both genetically obese mice and those with diet-induced obesity received GC-1 treatment daily.

The genetically obese mice lost weight and more than 50 per cent of their fat mass in approximately two weeks, according to Phillips. The treated mice also showed anti-diabetic effects, such as a six-fold improvement or better insulin sensitivity – how well the body clears glucose from the bloodstream. Mice with diet-induced obesity experienced similar improvements, said Phillips.

“Our data demonstrate that GC-1 is a novel fat-browning agent that may have a use in the treatment of obesity and metabolic disease,” added Phillips.

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome. Phillips said, however, that the doses of sobetirome used in cholesterol-lowering trials are much lower than what would be needed for weight loss.

A recent study found that obese people have fewer ‘pleasure receptors’ in their brains, which could explain their need to overeat.
RELATED STORIES
  Obese people's brains have fewer ‘pleasure receptors’: study


People with obesity have a significantly lower number of neurotransmitters dedicated to generating pleasurable sensations than people of a normal weight, according to a study, which could explain why they have difficulty restraining their eating.
  Cut sugar consumption to less than 10 per cent of daily energy intake: WHO


The World Health Organisation (WHO) has issued new guidelines on sugar consumption that say adults and children from most countries in the world should roughly halve the amount of sugar they eat to lower the risk of obesity and tooth decay.
  Childhood obesity campaign combines physical activity with altruism


Technogym is urging health clubs around the world to get their members moving during March with the added incentive of helping to tackle childhood obesity.
  Tackle obesity or risk losing benefits, says PM


David Cameron has outlined plans for tough new measures that could see obese people on sickness benefits have their income cut if they refuse treatment for the condition.
MORE NEWS
London Museum makes destination dining part of the attraction
London Museum will open four new food and drink destinations when it launches its new home at Smithfield on 28 November, making hospitality a central part of the visitor experience at one of the capital's biggest cultural openings of the year.
OMA completes New Museum transformation with landmark expansion and Oberon restaurant
OMA has completed a major transformation of New York's New Museum, creating a larger cultural campus that combines expanded exhibition spaces with learning, performance, hospitality and public programming.
David Rockwell creates immersive magic destination, The Hand and The Eye
A US$50 million (£44.2 million, €51.2 million) transformation of Chicago's historic McCormick Mansion has created a new destination that combines live magic, immersive theatre, dining and private membership under one roof.
Montana Heritage Center opens with immersive exhibits and US$107 million investment
The Montana Historical Society has officially celebrated the opening of its new Montana Heritage Center, a US$107 million (£79 million, €92 million) destination that combines immersive storytelling with cutting-edge audiovisual technology to bring the sta
+ More news   
LATEST JOBS
General Manager, The Needles
Heritage Great Britain
Salary: c£70,000pa + benefits + relocation support
Job location: Isle of Wight , United Kingdom
+ More jobs  

COMPANY PROFILES
Sally Corporation

Our services include: Dark ride design & build; Redevelopment of existing attractions; High-quality [more...]
IDEATTACK

IDEATTACK is a full-service planning and design company with headquarters in Los Angeles. [more...]
iPlayCO

iPlayCo was established in 1999. [more...]
DJW

David & Lynn Willrich started the Company over thirty years ago, from the Audio Visual Department [more...]
+ More profiles  
CATALOGUE GALLERY
 

+ More catalogues  
DIRECTORY
+ More directory  
DIARY

 

23-26 Aug 2026

Elevate Spa Riviera Maya Edition

The Riviera Maya Edition Kanai, Playa del Carmen, Mexico
28-29 Sep 2026

Wellness Destination AI Tech Summit – Tourism, Hospitality & Real Estate, 28-29 Sept 2026

Grand Ballroom, METT Singapore, Singapore
+ More diary  
LATEST ISSUES
+ View Magazine Archive

Attractions Management

2026 issue 1


View issue contents
View on turning pages
Download PDF
FREE digital subscription
Print subscription

Attractions Management

2025 issue 2


View issue contents
View on turning pages
Download PDF
FREE digital subscription
Print subscription

Attractions Management

2025 issue 1


View issue contents
View on turning pages
Download PDF
FREE digital subscription
Print subscription

Attractions Management

2024 issue 4


View issue contents
View on turning pages
Download PDF
FREE digital subscription
Print subscription

Attractions Management News

06 Apr 2020 issue 153


View on turning pages
Download PDF
View archive
FREE digital subscription
Print subscription

Attractions Handbook

2019


View issue contents
View on turning pages
Download PDF
FREE digital subscription
Print subscription
 
ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
 
ATTRACTIONS MANAGEMENT
ATTRACTIONS MANAGEMENT NEWS
ATTRACTIONS HANDBOOK
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS
ADVERTISE . CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2026
Get Attractions Management digital magazine FREE
Sign up here ▸
Jobs    News   Products   Magazine   Subscribe
NEWS
Experimental drug increases metabolic rate: study
POSTED 09 Mar 2015 . BY Helen Andrews
While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome Credit: Shutterstock / Andresr
An experimental drug has been found to speed up metabolism and burn off fat cells, according to a study conducted on hundreds of mice by the Houston Methodist Research Institute, US.

Dubbed ‘GC-1’, the drug works by activating the receptors for thyroid hormone, which play a role in regulating the metabolism – the body’s conversion of food into energy.

“CG-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat,” said the study’s author Kevin Phillips PhD.

Until several years ago, scientists thought that only animals and human infants had energy-burning “good” brown fat.

“It is now clear,” said Phillips, “that human adults do have brown fat, but it appears to lose its calorie-burning capacity over time.”

White adipose tissue, or fat, becomes a “metabolic villain” when the body has too much of it, according to Phillips. People with more brown fat have a reduced risk of obesity and diabetes, thus researchers are now working on ways to convert white fat into brown fat.

Phillips and other researchers tested the drug on hundreds of mice, with partial funding from the National Institutes of Health, according to ScienceDaily. Both genetically obese mice and those with diet-induced obesity received GC-1 treatment daily.

The genetically obese mice lost weight and more than 50 per cent of their fat mass in approximately two weeks, according to Phillips. The treated mice also showed anti-diabetic effects, such as a six-fold improvement or better insulin sensitivity – how well the body clears glucose from the bloodstream. Mice with diet-induced obesity experienced similar improvements, said Phillips.

“Our data demonstrate that GC-1 is a novel fat-browning agent that may have a use in the treatment of obesity and metabolic disease,” added Phillips.

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome. Phillips said, however, that the doses of sobetirome used in cholesterol-lowering trials are much lower than what would be needed for weight loss.

A recent study found that obese people have fewer ‘pleasure receptors’ in their brains, which could explain their need to overeat.
RELATED STORIES
Obese people's brains have fewer ‘pleasure receptors’: study


People with obesity have a significantly lower number of neurotransmitters dedicated to generating pleasurable sensations than people of a normal weight, according to a study, which could explain why they have difficulty restraining their eating.
Cut sugar consumption to less than 10 per cent of daily energy intake: WHO


The World Health Organisation (WHO) has issued new guidelines on sugar consumption that say adults and children from most countries in the world should roughly halve the amount of sugar they eat to lower the risk of obesity and tooth decay.
Childhood obesity campaign combines physical activity with altruism


Technogym is urging health clubs around the world to get their members moving during March with the added incentive of helping to tackle childhood obesity.
Tackle obesity or risk losing benefits, says PM


David Cameron has outlined plans for tough new measures that could see obese people on sickness benefits have their income cut if they refuse treatment for the condition.
MORE NEWS
London Museum makes destination dining part of the attraction
London Museum will open four new food and drink destinations when it launches its new home at Smithfield on 28 November, making hospitality a central part of the visitor experience at one of the capital's biggest cultural openings of the year.
OMA completes New Museum transformation with landmark expansion and Oberon restaurant
OMA has completed a major transformation of New York's New Museum, creating a larger cultural campus that combines expanded exhibition spaces with learning, performance, hospitality and public programming.
David Rockwell creates immersive magic destination, The Hand and The Eye
A US$50 million (£44.2 million, €51.2 million) transformation of Chicago's historic McCormick Mansion has created a new destination that combines live magic, immersive theatre, dining and private membership under one roof.
Montana Heritage Center opens with immersive exhibits and US$107 million investment
The Montana Historical Society has officially celebrated the opening of its new Montana Heritage Center, a US$107 million (£79 million, €92 million) destination that combines immersive storytelling with cutting-edge audiovisual technology to bring the sta
Universal launches new theme park model with Kids Resort
Universal Destinations and Experiences has launched a new regional theme park model with the opening of Universal Kids Resort in Frisco, Texas.
San Antonio Zoo reports $283 million economic impact as expansion plans progress
San Antonio Zoo has reported a US$283 million economic impact for 2025, following a decade- long transformation programme that has seen almost US$200 million invested into the Texas attraction.
+ More news   
 
COMPANY PROFILES
Sally Corporation

Our services include: Dark ride design & build; Redevelopment of existing attractions; High-quality [more...]
IDEATTACK

IDEATTACK is a full-service planning and design company with headquarters in Los Angeles. [more...]
iPlayCO

iPlayCo was established in 1999. [more...]
DJW

David & Lynn Willrich started the Company over thirty years ago, from the Audio Visual Department [more...]
+ More profiles  
CATALOGUE GALLERY
+ More catalogues  
DIRECTORY
+ More directory  
DIARY

 

23-26 Aug 2026

Elevate Spa Riviera Maya Edition

The Riviera Maya Edition Kanai, Playa del Carmen, Mexico
28-29 Sep 2026

Wellness Destination AI Tech Summit – Tourism, Hospitality & Real Estate, 28-29 Sept 2026

Grand Ballroom, METT Singapore, Singapore
+ More diary  
 


ADVERTISE . CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2026

ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
ATTRACTIONS MANAGEMENT NEWS
ATTRACTIONS HANDBOOK
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS